Carbapenem-hydrolyzing gram-negative bacteria: Current options for treatment and review of drugs in development

Foad I. Abandeh, Mark E. Drew, Madhuri M. Sopirala

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Multidrug resistant gram-negative bacteria are an increasing therapeutic challenge. The beta-lactamases are a group of enzymes that confer resistance to the beta-lactam antibiotics. The carbapenems have been in wide use to treat beta-lactamase producing, multidrug resistant gram-negative bacterial infections. However, the emergence of carbapenemases, enzymes capable of hydrolyzing the carbapenems, has limited our therapeutic options. In the recent years, there has been some development in the discovery of new agents such as boronic acid derivatives, ME1071 and Ca-EDTA that may enhance the activity of existing antibiotics, CTC-96 which reverses antibiotic resistance and polymyxin derivatives with decreased renal toxicity. While global efforts towards new drug development should continue, appropriate use of currently available antibiotics is equally important. In this review, we will discuss the general characteristics of carbapenemases, recent patents with drugs under development and current treatment options.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalRecent Patents on Anti-Infective Drug Discovery
Volume7
Issue number1
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Carbapenems
Gram-Negative Bacteria
beta-Lactamases
Anti-Bacterial Agents
Gram-Negative Bacterial Infections
Pharmaceutical Preparations
Polymyxins
Boronic Acids
beta-Lactam Resistance
Patents
Enzymes
Microbial Drug Resistance
Edetic Acid
Kidney
Therapeutics

Keywords

  • Beta-lactamases
  • Carbapenemases
  • Gram-negative bacteria
  • Multidrug resistant
  • Novel agents
  • Patent

ASJC Scopus subject areas

  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Carbapenem-hydrolyzing gram-negative bacteria : Current options for treatment and review of drugs in development. / Abandeh, Foad I.; Drew, Mark E.; Sopirala, Madhuri M.

In: Recent Patents on Anti-Infective Drug Discovery, Vol. 7, No. 1, 01.04.2012, p. 19-27.

Research output: Contribution to journalReview article

@article{50275eeade7f4894b554c12392ffc5bf,
title = "Carbapenem-hydrolyzing gram-negative bacteria: Current options for treatment and review of drugs in development",
abstract = "Multidrug resistant gram-negative bacteria are an increasing therapeutic challenge. The beta-lactamases are a group of enzymes that confer resistance to the beta-lactam antibiotics. The carbapenems have been in wide use to treat beta-lactamase producing, multidrug resistant gram-negative bacterial infections. However, the emergence of carbapenemases, enzymes capable of hydrolyzing the carbapenems, has limited our therapeutic options. In the recent years, there has been some development in the discovery of new agents such as boronic acid derivatives, ME1071 and Ca-EDTA that may enhance the activity of existing antibiotics, CTC-96 which reverses antibiotic resistance and polymyxin derivatives with decreased renal toxicity. While global efforts towards new drug development should continue, appropriate use of currently available antibiotics is equally important. In this review, we will discuss the general characteristics of carbapenemases, recent patents with drugs under development and current treatment options.",
keywords = "Beta-lactamases, Carbapenemases, Gram-negative bacteria, Multidrug resistant, Novel agents, Patent",
author = "Abandeh, {Foad I.} and Drew, {Mark E.} and Sopirala, {Madhuri M.}",
year = "2012",
month = "4",
day = "1",
doi = "10.2174/157489112799829675",
language = "English (US)",
volume = "7",
pages = "19--27",
journal = "Recent Patents on Anti-Infective Drug Discovery",
issn = "1574-891X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Carbapenem-hydrolyzing gram-negative bacteria

T2 - Current options for treatment and review of drugs in development

AU - Abandeh, Foad I.

AU - Drew, Mark E.

AU - Sopirala, Madhuri M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Multidrug resistant gram-negative bacteria are an increasing therapeutic challenge. The beta-lactamases are a group of enzymes that confer resistance to the beta-lactam antibiotics. The carbapenems have been in wide use to treat beta-lactamase producing, multidrug resistant gram-negative bacterial infections. However, the emergence of carbapenemases, enzymes capable of hydrolyzing the carbapenems, has limited our therapeutic options. In the recent years, there has been some development in the discovery of new agents such as boronic acid derivatives, ME1071 and Ca-EDTA that may enhance the activity of existing antibiotics, CTC-96 which reverses antibiotic resistance and polymyxin derivatives with decreased renal toxicity. While global efforts towards new drug development should continue, appropriate use of currently available antibiotics is equally important. In this review, we will discuss the general characteristics of carbapenemases, recent patents with drugs under development and current treatment options.

AB - Multidrug resistant gram-negative bacteria are an increasing therapeutic challenge. The beta-lactamases are a group of enzymes that confer resistance to the beta-lactam antibiotics. The carbapenems have been in wide use to treat beta-lactamase producing, multidrug resistant gram-negative bacterial infections. However, the emergence of carbapenemases, enzymes capable of hydrolyzing the carbapenems, has limited our therapeutic options. In the recent years, there has been some development in the discovery of new agents such as boronic acid derivatives, ME1071 and Ca-EDTA that may enhance the activity of existing antibiotics, CTC-96 which reverses antibiotic resistance and polymyxin derivatives with decreased renal toxicity. While global efforts towards new drug development should continue, appropriate use of currently available antibiotics is equally important. In this review, we will discuss the general characteristics of carbapenemases, recent patents with drugs under development and current treatment options.

KW - Beta-lactamases

KW - Carbapenemases

KW - Gram-negative bacteria

KW - Multidrug resistant

KW - Novel agents

KW - Patent

UR - http://www.scopus.com/inward/record.url?scp=84858320494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858320494&partnerID=8YFLogxK

U2 - 10.2174/157489112799829675

DO - 10.2174/157489112799829675

M3 - Review article

C2 - 22211694

AN - SCOPUS:84858320494

VL - 7

SP - 19

EP - 27

JO - Recent Patents on Anti-Infective Drug Discovery

JF - Recent Patents on Anti-Infective Drug Discovery

SN - 1574-891X

IS - 1

ER -